NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with F-Star Therapeutics, Limited.
Click here to learn more and participate in the action.
On July 29, 2020, Spring Bank announced that it had signed an agreement to be acquired by F-Star Therapeutics. Pursuant to the merger agreement, Spring Bank stockholders will own approximately 38.8% of the combined company along with two contingent value rights (“CVRs”) related to Spring Bank’s STING agonist and STING antagonist programs.
Bragar Eagel & Squire is concerned that Spring Bank’s board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Spring Bank’s stockholders.
If you own shares of Spring Bank and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at firstname.lastname@example.org or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.